Imatinib mesylate -Gleevec®, STI571-is an oral cancer drug that selectively inhibits several protein tyrosine kinases associated with human malignancy. The drug is used for the treatment of chronic myeloid leukemia, malignant gastrointestinal stromal tumors, and some other conditions. Treatment with imatinib is generally well tolerated but is not without the risk of adverse effects. Various types of skin eruptions have been reported. Cutaneous side effects with this treatment are common but a lichenoid drug eruption is rare. In this article, we report a 46-year-old woman who presented with lichen planus like lesions on the trunk and extremities, and oral mucosa due to the use of imatinib mesylate for the chronic myeloid leukemia. The literature on lichenoid drug eruption due to imatinib mesylate is reviewed.
INTRODUCTION
Chronic myelogeneous leukemia (CML) is a clonal myeloproliferative disorder which is the first human malignancy to be associated with a specific genetic lesion, the Philadelphia chromosome, carrying BCR-ABL oncogene. Imatinib (Gleevec) is the first molecularly targeted drug developed for CML and has achieved a remarkable success (1) (2) (3) . Few side effects are reported with imatinib consisting of mainly hematologic side effects such as neutropenia and thrombocytopenia. Cutaneous side effects with this treatment are common but a lichenoid drug eruption is rare (4) .
CASE REPORT
A 46 year-old female with an approximately 15-month history of CML presented with grey-violaceous plaques with a reticular pattern on both cheek mucosal surfaces (Figure 1) , and a disseminated purple, prurigenous papules on the trunk, legs, and arms ( Figure 2 ). Dermatological findings were suggestive of lichen planus. She had splenomegaly other than the cutaneous eruption. She had been treated with Gleevec® (Novartis, USA) 400 mg daily for 3 months before onset of the rash. She stated that the eruption spread in the last three weeks.
The punch biopsy taken from the trunk and oral mucosa revealed a lichenoid band of lymphocytes and histiocytes, hypergranulosis, and vacuolar degeneration in the basal layer ( Figure 3 ). The histopathological findings were consistent with lichenoid eruption. The patient was given triamcinolone 0.1% cream topically and oral antihistaminic, which produced improvements in the lesions. 
DISCUSSION
Imatinib shows its effect by competitively inhibiting the adenosine triphosphate -binding site of the protein kinase enzyme, leading to the inhibition of tyrosine phosphorilation of proteins involved in BCR-ABL gene without affecting normal cells (1) . Imatinib also shows its effect on the platelet derived growth factor and c-kit. Recently, it has been shown that imatinib has antifibrogenic effect on bone marrow fibrosis in CML (2) . Except from CML, imatinib has also shown to be effective among idiopathic hypereosinophilic syndrome and gastrointestinal stromal tumors (1) . There are few reports concerning the side effects of the drug. Hematologic alterations like leukopenia or thrombocytopenia, or trombocytosis and leukocytosis are all reported (3). Non-lichenoid cutaneous reactions secondary to imatinib have been well described and are the most common non-hematologic adverse events associated with its use. The most common cutaneous reactions include morbilliform eruptions and cutaneous edema, particularly, periorbital edema. Cases of severe generalized skin eruptions such as erythema multiforme, acute generalized exanthemous pustulosis, and toxic epidermal necrolysis have also been reported with imatinib use (4). Although skin reactions resulting from imatinib have been well-described, reports of an associated lichenoid dermatitis are rare. Since 2002, there have been twenty case reports of lichenoid eruptions, sixteen of which were in the context of CML treatment, and the others of GIST treatment (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Twenty case reports, including our case, are summarized in Table 1 . Three cases had oral involvement as the only manifestation (5-7) , seven had only cutaneous manifestations (8) (9) (10) (11) (12) (13) (14) , and the others presented with mucocutaneous involvement (15) (16) (17) (18) (19) . Our patient presented with grey-violaceous plaques with a reticular on both cheek mucosal surfaces, and a disseminated cutaneous eruption composed of dark purple, prurigenous papules appeared on the trunk, legs and arms . The appeaerance of the majority of the lichenoid lesions was within 2-3 months (8) (9) (10) (11) (12) (13) (14) . In some reported cases, the withdrawal of imatinib treatment was necessary (5, 18) . In other cases, dose adjustment and treatment with topical and/or corticosteroids allowed for the continuation of imatinib treatment (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) 19) . In two cases, oral acitretin improved the lesions (11). In our case, topical corticosteroids improved the lichenoid lesions.
Cutaneous reactions to imatinib appear to be dose-related, appearing more frequently and severely in patients on doses of 600 mg daily or greater. However lichenoid eruption may occur under the standard dose of Imatinib (400 mg/day) (1,7).
CONCLUSION
The early recognition and treatment of cutaneous adverse effects may allow for the continued administration of imanitib. With an increasing number of patients being treated with imatinib, clinicians should be aware of its side effect, even in the standard dose of the drug, and we anticipate further reports of lichenoid and other cutaneous reactions associated with its use.
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